News Column

Studies from University of Tubingen Have Provided New Information about Stem Cells

June 4, 2014

By a News Reporter-Staff News Editor at Biotech Week -- Investigators publish new report on Stem Cell Research. According to news originating from Tubingen, Germany, by NewsRx correspondents, research stated, "The aim of this study was to find a new and less cardiotoxic conditioning regimen for high-dose chemotherapy and autologous stem cell transplantation (aSCT) in patients with severe SSc and pre-existing cardiac involvement. Six patients with cardiac involvement were treated for SSc with a conditioning regimen including reduced-dose CYC plus the non-cardiotoxic alkylant thiotepa."

Our news journalists obtained a quote from the research from the University of Tubingen, "All patients received an implantable cardioverter defibrillator (ICD) before aSCT. The response at months 6 and 12 was measured according to reduction of the modified Rodnan skin score (mRSS). CT histography was used to monitor pulmonary manifestations, as were echocardiography, N-terminal pro-brain natriuretic peptide (NT-proBNP) and troponin for the cardiac involvement. Cardiac events were defined as death or hospitalisation due to heart failure or appropriate discharge of the ICD. Between December 2008 and May 2012, four male and two female patients with a median age of 41 years received aSCT. The median mRSS significantly decreased from 26.5 to 18 and 17.5 at month 6 and 12, respectively. The total lung volume also significantly improved. Within the median follow-up of 1.6 years (range 1-3.8) two patients experienced a relapse of SSc, which results in a progression-free survival rate of 66.6%. Three patients experienced ICD discharge. For patients with SSc and cardiac involvement, the use of thiotepa and reduced-dose CYC is feasible and effective. The rate of ICD discharge underlines the need for protection in these endangered patients."

According to the news editors, the research concluded: "This preliminary experience allowed us to use this regimen for our currently recruiting prospective trial (NCT01895244)."

For more information on this research see: Autologous stem cell transplantation with thiotepa-based conditioning in patients with systemic sclerosis and cardiac manifestations. RHEUMATOLOGY, 2014;53(5):919-922. RHEUMATOLOGY can be contacted at: Oxford Univ Press, Great Clarendon St, Oxford OX2 6DP, England. (Oxford University Press -; RHEUMATOLOGY -

The news correspondents report that additional information may be obtained from J.C. Henes, University of Tubingen, Dept. of Cardiol & Cardiovasc Med, D-72076 Tubingen, Germany. Additional authors for this research include I. Koetter, M. Horger, M. Schmalzing, K. Mueller, C. Eick, A. Bauer, W. Vogel and L. Kanz (see also Stem Cell Research).

Keywords for this news article include: Drugs, Europe, Germany, Surgery, Tubingen, Cardiology, Chemotherapy, Stem Cell Research, Cell Transplantation, Implantable Cardioverter Defibrillator

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

For more stories covering the world of technology, please see HispanicBusiness' Tech Channel

Source: Biotech Week

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters